DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The "Caspases Activators -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Caspases Activators - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Caspases Activators development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Caspases Activators - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Caspases Activators - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Caspases Activators Pipeline Products in Clinical Stages

6. Caspases Activators Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned

Nereus Pharmaceuticals PharmaMar Conatus Pharma Aptose Biosciences

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4wn7r4/caspases?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005237/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/24/2018 10:11 AM/DISC: 08/24/2018 10:11 AM

http://www.businesswire.com/news/home/20180824005237/en